Physician profile
Benjamin Farahnik
NPI 1699209254
$198,454.32
in general payments reported to CMS, 2019-2025
37 companies · $174K in 2025
The $174K reported for 2025 was more than what 93% of Clinical & Laboratory Dermatological Immunology providers received nationally (typical 2025 total: $1,130).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $137 · 2021: $131 · 2022: $1,630 · 2023: $3,199 · 2024: $19K · 2025: $174K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $161K · Food and Beverage: $19K · Consulting Fee: $9,230 · Travel and Lodging: $7,584 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $160,728.00 |
| Food and Beverage | $18,781.56 |
| Consulting Fee | $9,230.00 |
| Travel and Lodging | $7,583.81 |
| Education | $120.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $76,012.92 | 2022-2025 | Bimzelx, Cimzia |
| Botanix Sb INC | $55,915.49 | 2025 | Sofdra |
| Amgen INC. | $53,524.51 | 2022-2025 | Otezla, Otezla |
| Abbvie INC. | $2,641.20 | 2020-2025 | |
| Genzyme Corporation | $1,733.06 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,253.68 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $984.60 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| Leo Pharma INC. | $900.33 | 2022-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $773.85 | 2022-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $680.76 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $496.90 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $488.83 | 2023-2025 | |
| Galderma Laboratories, L.P. | $439.82 | 2019-2025 | Nemluvio, Aklief |
| Incyte Corporation | $360.73 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $301.25 | 2021-2025 | Odomzo, Blu-U, Winlevi |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $253.43 | 2024-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.74 | 2023-2025 | Spevigo |
| Almirall LLC | $224.66 | 2022-2025 | Seysara, Klisyri |
| Merz North America, INC. | $176.98 | 2022-2024 | |
| Strata Skin Sciences, INC. | $153.38 | 2024-2025 | Xtrac |
| Dermavant Sciences, INC. | $135.50 | 2023 | Vtama |
| Biofrontera INC. | $108.97 | 2022-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Revance Therapeutics, INC. | $92.00 | 2024-2025 | Daxxify |
| Mayne Pharma Commercial LLC | $91.77 | 2021-2025 | |
| Journey Medical Corporation | $84.48 | 2022-2025 | |
| Kyowa Kirin, INC. | $50.44 | 2023-2024 | Poteligeo |
| Organon LLC | $45.82 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $43.13 | 2023 | Ycanth |
| Blueprint Medicines Corporation | $36.12 | 2025 | Ayvakit |
| Allergan, INC. | $34.32 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $33.62 | 2023 | Valchlor |
| Genentech USA, INC. | $32.67 | 2022 | |
| Sandoz INC. | $27.05 | 2024 | Hyrimoz |
| Lifenet Health | $25.56 | 2023 | |
| Fresenius Kabi USA, LLC | $25.11 | 2023 | Idacio |
| Lnhc, INC | $24.34 | 2025 | Zelsuvmi |
| Solta Medical, A Division of Bausch Health US, LLC | $19.30 | 2024 | Clear & Brilliant, Fraxel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Farahnik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.